French limit conditions and prices for heart leads
This article was originally published in Clinica
Manufacturers of leads used in implantable heart stimulation devices, such as pacemakers, have until March 2 to comment on two proposals just published in the French Journal officiel that will impact conditions for reimbursement and the prices they can charge. The first of the two proposals, drafted by the French commission responsible for the evaluation of healthcare products and services, CEPP, lists the various conditions of use which must be met when the various leads are implanted. The second, drafted by the healthcare products pricing committee, the CEPS, proposes upper limits of prices that can be charged and reimbursed for these different types of leads, which are set at E540 ($654) for most leads except for those used in transvenous stimulation, which are set at E850. The proposals were published in the JO on January 31.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.